About Curie.Bio
Curie.Bio, an accelerator and incubator program founded in 2022, is based in Boston, United States. With a presence in 2 countries, it has supported around 16 startups in sectors like Life Sciences, High Tech. As of Nov 2026, Curie.Bio has witnessed 10 portfolio exits. Most notable companies in
its portfolio include Flatiron Health, Tango Therapeutics and Relay Therapeutics. The program is backed by a team of 39 people who primarily support Seed startups based in United States. Its latest investment was a $120M Post IPO round in Bolt Biotherapeutics on Oct 23, 2026, which also saw participation from Deep Track Capital and ADAR1 Capital Management.
Key Metrics
Founded Year
2022
Location
Boston, United States
Portfolio Companies
Sectors of Investment
Stages of Investment
Seed, Post IPO & 1 more
Locations of Investment
Curie.Bio's List of Top Investments
Curie.Bio has a portfolio of 16 companies. Their most notable investmentis in Alkira BioTheir portfolio spans across United States and Australia. They have invested in Life Sciences, High Tech, Enterprise Applications and 1 other sectors, across stages such as Seed, Post IPO and 1 more. Here is the list of top investments by Curie.Bio:Cloud-based practice management tool for providers. The company's OncologyCloud platform includes the electronic medical record for oncology, an analytics section for business clinical intelligence, a patient portal, and integrated billing management which allows cancer care providers and life sciences companies to track metrics related to cancer care, match patients to clinical trials and automate data collection.
Key facts about Flatiron Health
- Founded Year: 2012
- Location: New York City (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $314M
- Employee Count: 1,447 as on Sep 30, 2026
- Investors: Allen & Company, Baillie Gifford and 27 Others
- Latest Funding Round: Series C, Jan 06, 2016, $*****
- Highlight: Acquired
Tango Therapeutics is a biotech company developing novel drugs for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening to identify targets for specific subgroups of cancer patients. The company is discovering novel targets using synthetic lethality, where the cancer-causing alteration in a tumour suppressor gene creates a vulnerability that leads to the destruction of the tumour cell.
Key facts about Tango Therapeutics
- Founded Year: 2017
- Location: Cambridge (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $165M
- Employee Count: 181 as on Sep 30, 2026
- Investors: Bain Capital Life Sciences, Boxer Capital and 8 Others
- Latest Funding Round: Post IPO, Oct 24, 2025, $*****
- Highlight: Public
Relay Therapeutics is a developer of a drug discovery platform and study protein motion. The company’s drug discovery engine provides 3D visuals on the mobility of a protein to study or analyze the function of protein-based on its motion. It also enables the researchers to study the ligand-binding pockets present in the protein and detect ligand-protein binding interactions. The company’s initial program focuses on developing therapeutics in oncology.
Key facts about Relay Therapeutics
- Founded Year: 2016
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $520M
- Employee Count: 230 as on Sep 30, 2026
- Investors: HTIF, Colt Ventures and 17 Others
- Latest Funding Round: Post IPO, Jan 10, 2024, $*****
- Highlight: Public
Developer of selective kinase inhibitors for patients with genomically defined cancers. Their approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Their ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets.
Key facts about Blueprint Medicines
- Founded Year: 2008
- Location: Cambridge (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2024
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $115M
- Employee Count: 674 as on Sep 30, 2026
- Investors: BVF Partners, Foresite Capital and 20 Others
- Latest Funding Round: Post IPO, Jun 30, 2022, $*****
- Highlight: Acquired
Provider of genomics-based diagnostics test for cancer. The company's clinical assays, FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies and sarcomas, and the liquid biopsy test FoundationACT provide a complete genomic profile of cancers, which oncologists can use to inform their treatment decisions. In addition, all tests provide an estimate of tumor mutational burden that enables oncologists to predict immunotherapy response as well.
Key facts about Foundation Medicine
- Founded Year: 2010
- Location: Cambridge (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2017
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $96.5M
- Employee Count: 1,761 as on Sep 30, 2026
- Investors: Curie.Bio, Redmile Group and 11 Others
- Latest Funding Round: Series B, Jan 08, 2013, $*****
- Highlight: Acquired
Curie.Bio's Year-on-Year Investment Trends
Curie.Bio has invested in 16 companies over the last 4 years, with an average of 1 new investment annually in the last 3 years. As of Oct 2026, it has made 3 investments in this year. Its most recent first time investment was in Bolt Biotherapeutics and most recent follow-on round was in R1 Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 2 | 1 | 3 |
2025 | 0 | 0 | 0 |
2024 | 1 | 0 | 1 |
2023 | 0 | 0 | 0 |
2022 | 1 | 0 | 1 |
Curie.Bio's Investments by Stage
Curie.Bio has made 2 investments in Seed stage with an average round size of $5M, 1 investment in Post IPO stage with an average round size of $120M and 1 investment in Series A stage with an average round size of $77.5M.Stage of entry | No. of Investments |
|---|---|
Seed | 2 |
Post IPO | 1 |
Series A | 1 |
Note: We have considered here, only first round of investments
Curie.Bio's Investments by Sector
Curie.Bio has a portfolio focused on Life Sciences. Notably, it has invested in 15 Enterprise (B2B) companies, 15 Tech companies, 2 Software companies and at least 1 company focusing on AI-Native.Curie.Bio's Investments by Geography
Curie.Bio has made most investments in United States (3), followed by Australia where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 3 |
Australia | 1 |
Note: We have considered here, only first round of investments
Curie.Bio's recent investments
Curie.Bio has made 3 investments in 2026 so far. Bolt Biotherapeutics and R1 Therapeutics are the latest among them.Here are the most recent investments by Curie.Bio:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 23, 2026 | United States | Post IPO | 6084 | [+10] | |
Sep 30, 2026 | United States | Series A | 5956 | [+5] | |
Mar 17, 2026 | United States | Series A | 5415 | [+4] | |
Jul 25, 2024 | Australia | Seed | 8849 | - | |
Aug 01, 2022 | United States | Seed | 9811 | - |
IPOs and Publicly Listed companies in Curie.Bio's Portfolio
5 of Curie.Bio's portfolio companies have become public. Bolt Biotherapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2021 at marketcap of $690M and Tango Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $186M.Here are Curie.Bio's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 05, 2021 | Oct 23, 2026 | Post IPO | 6511 | |
Sep 04, 2020 | - | - | 9281 | |
Jul 16, 2020 | - | - | 1854 | |
Feb 13, 2020 | - | - | 3913 | |
May 24, 2018 | - | - | 6683 |
Acquired companies in Curie.Bio's Portfolio
5 companies from Curie.Bio's portfolio have been acquired. The most recent acquisition was Blueprint Medicines in Jun 2025 by Sanofi for $*****.Here are Curie.Bio's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 02, 2025 | - | - | 4607 | |
Aug 01, 2023 | - | - | 9088 | |
Sep 01, 2022 | - | - | 4825 | |
Feb 15, 2018 | - | - | 8946 | |
Jan 12, 2015 | - | - | 9578 |
Team profile of Curie.Bio
Curie.Bio has a team of 39 members including 18 Partners and 14 Principals located in United States and Switzerland. Curie.Bio's team does not sit on the board of any company as of now.Here is a list of top team members in Curie.Bio:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | United States | - | ||
Partner | Boston | - | ||
Partner | - | - | ||
Partner | Cambridge | - | ||
Partner | Boston | - | - | |
Partner | Boston | - | ||
Partner | Switzerland | - | - | |
Partner | Boston | - | ||
Partner | San Francisco | - | ||
Partner | Boston | - | ||
Partner | San Diego | - | - |
Co-investors of Curie.Bio
Over the past 4 years, 27 investors have co-invested in Curie.Bio's portfolio companies. This includes funds and angels.
- Invested before Curie.Bio: Novo Holdings, Vivo Capital and 7 others have invested in rounds before Curie.Bio. There is 1 company where Novo Holdings has invested before Curie.Bio and 1 company where Vivo Capital has invested before Curie.Bio.
- Top Co-investors of Curie.Bio: 16 investors entered a company along with Curie.Bio. These include investors like Deep Track Capital (1 company).
- Invested after Curie.Bio: Samsara BioCapital (1 company) and Snma Group (1 company) are the investors which have invested in Curie.Bio's portfolio after their investments.
Recent News related to Curie.Bio
•
Renal Disease Biotech R1 Therapeutics Nabs $77.5M for Phase 2bEndpoints•Mar 17, 2026•R1 Therapeutics, Alebund, Curie.Bio, DaVita Venture Group and 3 others
•
VC firm's new $340M seed fund; Watertown biotech raises $185MThe Business Journals•Feb 06, 2025•Curie.Bio
•
Alkira Bio exits stealth via seed round to develop GPCR-targeting antibodiesBioWorld•Oct 23, 2024•Alkira Bio, Curie.Bio
•
Biotech fund Curie.Bio augments reserves with $380m to boost startupsPharmaceutical Technology•Jun 27, 2024•Curie.Bio
•
Curie.Bio Adds $380M Series A Fund to Move Biotech Startups to ClinicBioSpace•Jun 26, 2024•Curie.Bio
•
•
•
Differentiated Therapeutics Raises $5M in Seed FundingFinSMEs•Aug 01, 2022•Differentiated Therapeutics, Curie.Bio
